• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ERDAFITINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • ERDAFITINIB chembl:CHEMBL3545376 ApprovedAntineoplastic

    Alternate Names:

    BALVERSA
    ERDAFITINIB
    JNJ-42756493
    COMPOUND 4 [WO2011135376]
    chemidplus:1346242-81-6
    drugbank:12147
    pubchem.compound:67462786
    chembl:CHEMBL3545376

    Drug Info:

    (4 More Sources)

    Publications:

    Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
    Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
    Loriot Y et al., 2019, Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma., N Engl J Med
    Nishina T et al., 2018, Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors., Invest New Drugs
    Di Stefano et al., 2015, Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma., Clin. Cancer Res.
    Patani et al., 2016, Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use., Oncotarget
  • ERDAFITINIB   FGFR3

    Interaction Score: 1.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    28341788 25609060 26992226 26324363 31340094 28965185


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • ERDAFITINIB   FGFR2

    Interaction Score: 1.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type urinary system cancer
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26324363 28341788 31340094 28965185


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • ERDAFITINIB   FGFR1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    28341788 26324363 28965185


    Sources:
    JAX-CKB TTD OncoKB

  • ERDAFITINIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28341788


    Sources:
    JAX-CKB

  • ERDAFITINIB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28341788


    Sources:
    JAX-CKB

  • ERDAFITINIB   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • JAX-CKB: JNJ-42756493

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
    Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
    Di Stefano et al., 2015, Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma., Clin. Cancer Res.

  • CIViC: ERDAFITINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
    Loriot Y et al., 2019, Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma., N Engl J Med

  • TTD: JNJ-42756493

    • Version: 2020.06.01

    Alternate Names:
    D0EE8V TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Erdafitinib

    • Version: 2020.06.01

    Alternate Names:
    D0NW0T TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3545376

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Erdafitinib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: erdafitinib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Erdafitinib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21